Cap Alter Pharma

Cap-Alter Pharma is a French biotechnology company focused on developing innovative cancer therapies by targeting the protein translation initiation complex. The company specifically targets the eIF4E (eukaryotic translation initiation factor 4E) protein, which is frequently overexpressed in various aggressive cancers and plays a critical role in the translation of oncogenic mRNAs. By developing small molecule inhibitors that disrupt the cap-binding activity of eIF4E, Cap-Alter Pharma aims to suppress the production of proteins essential for tumor growth, survival, and metastasis. Their lead programs are currently in the pre-clinical stage, with a primary focus on difficult-to-treat indications such as triple-negative breast cancer and glioblastoma.